Display options
Cite
Mazouni C, Fina F, Romain S, et al. Outcome of Epstein-Barr virus-associated primary breast cancer. Mol Clin Oncol. 2014;3(2):295-298doi: 10.3892/mco.2014.459.
Mazouni, C., Fina, F., Romain, S., Ouafik, L., Bonnier, P., & Martin, P. M. (2015). Outcome of Epstein-Barr virus-associated primary breast cancer. Molecular and clinical oncology, 3(2), 295-298. https://doi.org/10.3892/mco.2014.459
Mazouni, Chafika, et al. "Outcome of Epstein-Barr virus-associated primary breast cancer." Molecular and clinical oncology vol. 3,2 (2015): 295-298. doi: https://doi.org/10.3892/mco.2014.459
Mazouni C, Fina F, Romain S, Ouafik L, Bonnier P, Martin PM. Outcome of Epstein-Barr virus-associated primary breast cancer. Mol Clin Oncol. 2015 Mar;3(2):295-298. doi: 10.3892/mco.2014.459. Epub 2014 Nov 20. PMID: 25798256; PMCID: PMC4360834.
Copy Download .nbib Format: NLM
Share it on

Mol Clin Oncol. 2015 Mar;3(2):295-298. doi: 10.3892/mco.2014.459. Epub 2014 Nov 20.

Outcome of Epstein-Barr virus-associated primary breast cancer.

Molecular and clinical oncology

Chafika Mazouni, Frédéric Fina, Sylvie Romain, L'houcine Ouafik, Pascal Bonnier, Pierre-Marie Martin

Affiliations

  1. Transfer Laboratory of Biological Oncology, Public Assistance Hospitals of Marseille, Northern Faculty of Medicine, Marseille ; Department of General Surgery, Institute Gustave Roussy, Villejuif.
  2. Transfer Laboratory of Biological Oncology, Public Assistance Hospitals of Marseille, Northern Faculty of Medicine, Marseille.
  3. Institute of Surgery and Gynecological and Breast Oncology, Beauregard Hospital, Marseille, France.

PMID: 25798256 PMCID: PMC4360834 DOI: 10.3892/mco.2014.459

Abstract

The presence of the Epstein-Barr-virus (EBV) has been reported to be a pathogenic factor in breast cancer (BC). We previously demonstrated the aggressiveness of EBV-positive BC. The purpose of the present study was to evaluate the effect of EBV on the prognosis of BC according to the BC phenotype. A total of 117 patients with primary BC previously tested for the presence of EBV were evaluated. The presence of the virus was evaluated in breast specimens using quantitative PCR (qPCR). Disease-free survival (DFS) and overall survival (OS) were evaluated for 4 molecular subtypes, namely luminal A and B (lumA and lumB, respectively), human epidermal growth factor receptor 2 (HER2) and triple-negative (TN) subtypes and according to the EBV status. EBV positivity was observed in 32.5% of the cases. TN, HER2 and lumB tumours were more frequent among EBV-BC cases (P=0.02). The DFS rates were different between BC subtypes (P=0.002), but the differences were not statistically significant when the cases were stratified according to the EBV status (P=0.08 for EBV-negative and 0.06 for EBV-positive cases). The OS rates were similar for BC subtypes (P= 0.50) and when the cases were stratified according to the EBV status (P=0.16 and P=0.67 for EBV-positive and -negative cases, respectively). EBV was not associated with DFS or OS, in contrast to BC phenotypes, tumour size or nodal status. Therefore, EBV positivity was found to exert no effect on survival, despite its association with aggressive BC phenotypes.

Keywords: Epstein-Barr virus; breast cancer; molecular types; survival

References

  1. Nature. 2000 Aug 17;406(6797):747-52 - PubMed
  2. Infect Agent Cancer. 2011 Jun 23;6(1):7 - PubMed
  3. Br J Cancer. 2011 Apr 12;104(8):1362-3; author reply 1364 - PubMed
  4. Breast Cancer Res Treat. 2012 Aug;135(1):1-15 - PubMed
  5. Ann Oncol. 2011 Aug;22(8):1736-47 - PubMed
  6. J Cancer Res Clin Oncol. 2007 Jan;133(1):13-21 - PubMed
  7. Br J Cancer. 2001 Mar 23;84(6):783-90 - PubMed
  8. Clin Cancer Res. 2005 Aug 15;11(16):5678-85 - PubMed
  9. Br J Cancer. 2011 Jan 18;104(2):332-7 - PubMed
  10. Cancer Res. 1995 Jan 1;55(1):39-45 - PubMed

Publication Types